

CV



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 275 550 B1**

EUROPEAN PATENT SPECIFICATION

Date of publication of patent specification: 21.04.93 Int. Cl.⁵: A61K 9/70, A61L 15/16

Application number: 87119279.5

Date of filing: 28.12.87

The file contains technical information submitted after the application was filed and not included in this specification

Adhesive device for application to body tissue.

Priority: 24.12.86 JP 310993/86

Date of publication of application:
27.07.88 Bulletin 88/30

Publication of the grant of the patent:
21.04.93 Bulletin 93/16

Designated Contracting States:
CH DE FR GB IT LI SE

References cited:
EP-A- 0 072 251
DE-U- 8 624 190

CHEMICAL ABSTRACTS, vol. 83, no. 12, 22
September 1975, Columbus, OH (US); p. 373,
no. 103302*

CHEMICAL ABSTRACTS, vol. 102, no. 22, 03
June 1985, Columbus, OH (US); p. 402, no.
191207e*

CHEMICAL ABSTRACTS, vol. 106, no. 24, 15
June 1987, Columbus, OH (US); p. 357, no.
201772j*

Proprietor: TEIKOKU SEIYAKU KABUSHIKI
KAISHA

567 Sanbonmatsu Ochi-cho
Okawa-gun Kagawa-ken(JP)

Inventor: Yanagibashi, Norio
Shakujidai 4-10-8-201

Nerima-ku Tokyo(JP)
Inventor: Iwasaki, Setsuo
Uemakuri 321-9

Koshigaya-shi Saitama-ken(JP)

Inventor: Mizobushi, Tadafumi
Ohaza Shido 1416-1 Shido-cho
Ohkawa-gun Kagawa-ken(JP)

Inventor: Konishi, Ryoji
Sanbonmatsu 1989-86 Ochi-cho

Ohgawa-gun Kagawa-ken(JP)

Inventor: Konishi, Tatsuya
Sanbonmatsu 1278-1 Ochi-cho

Ohkawa-gun Kagawa-ken(JP)

Inventor: Wato, Takahiko
Matsubara 1234-17 Shirotori-cho
Ohgawa-gun Kagawa-ken(JP)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 275 550 B1

EP 0 275 550 B1

CHEMICAL ABSTRACTS, vol. 107, no. 16, 19
October 1987, Columbus, OH (US);
G.PONCHEL et al., p. 434*

⑦ Representative: Greenstreet, Cyril Henry et al
Haseltine Lake Partners Motorama Haus 502
Rosenheimer Strasse 30
W-8000 München 80 (DE)

DescriptionField of the Invention:

5 The present invention relates to novel adhesive devices for application to body tissue, to various processes for the preparation thereof, and to the use of such novel adhesive devices for sustained drug release and for protection of body tissue. In a preferred embodiment, the adhesive device is applied to the oral cavity. When applied to the oral cavity, the oral adhesive device sticks to oral mucosa or the tooth easily due to adhesiveness upon swelling or dissolution of the adhesive layer.

10 When used to protect wounds, diseased areas or other "ailing sites," therapy is efficient because of protection of the ailing sites and sustained drug release to the mucosal membrane, tooth or saliva.

Description of the Prior Art:

15 It has been known in this art to use various adhesive devices for the sustained release of drugs. Water soluble polymers dispersed in Plastibase are described in Japanese Takkaisho 51-38412 and Takaisho 53-86011. A tablet or sheet of polymer which becomes adhesive when contacted with saliva is disclosed by the following Japanese Tokkaisho: 54-41320, 54-41321, 55-62012, 55-92334, 55-83715, 55-84166, 55-84167, 55-83709, 55-83710, 56-18912, 56-68608, 58-213709, 59-48409, 59-181218, 59-186913, 59-232552, 59-232553, 60-116030, 60-116631, 60-215622. In particular, 59-232553 discloses buccal tapes in which the adhesive layer comprises polyacrylic acid and a water-soluble cellulose derivative and which may include a pharmaceutical compound for absorption by the mucous membranes.

A sheet made from a mixture of acrylic acid polymer and another polymer is disclosed by Takkaisho 61-249473.

25 The above devices, however, have the problems of relatively short residence time, insufficient protection of the ailing sites because of the lack of physical strength of the device itself, and foreign body sensation upon use, that is, a feeling of protrusion.

Further, a sheet made from a mixture of acrylic acid polymer (e.g. carboxyl- vinyl polymer) and polyvinyl acetate does not have enough adhesiveness and further shows a decrease in adhesiveness at 6 months after preparation.

Japanese Tokai 75-19838 discloses adhesives for bandages comprising a water-insoluble alkyl-acrylate containing polymer and cellulose derivatives.

SUMMARY OF THE INVENTION

35 It is accordingly an object of the invention to provide an adhesive device for application to body tissue such as the oral cavity.

It is another object of the invention to provide an adhesive device, as above, which easily adheres to the ailing site.

40 It is yet another object of the invention to provide an adhesive device, as above, having a good residence time.

It is still another object of the invention to provide an adhesive device, as above, which does not peel off during normal activity such as drinking or conversation.

45 It is yet another object of the invention to provide an adhesive device, as above, which does not give a foreign body sensation.

It is still another object of the invention to provide an adhesive device, as above, which is easy to use, and which provides the sustained release of a pharmaceutical preparation into the body tissue or saliva.

50 According to the invention an adhesive device for application to body tissue comprises an adhesive layer having an adhesive surface adherable to body tissue and a water insoluble or sparingly water soluble backing layer secured over a surface of the adhesive layer opposite the adhesive surface, wherein the adhesive layer comprises a mixture of at least one acrylic acid polymer that is soluble or swellable in water to show adhesiveness and a water-insoluble cellulose derivative.

55 The invention includes as another aspect the use of such an adhesive device as the vehicle for a pharmaceutical compound, thus providing the sustained release of a drug to an individual. For this purpose the device is applied to a body tissue of the individual, when on contact with a bodily fluid the pharmaceutical preparation is released into the body tissue and or the bodily fluid.

BRIEF DESCRIPTION OF THE DRAWING

The single figure illustrates the release rate of dibucaine hydrochloride in an adhesive device of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the present invention, a sheet-like adhesive layer which includes an acrylic acid polymer exhibiting adhesiveness upon dissolution or swelling, and a water insoluble cellulose derivative, is secured to a backing layer which is water insoluble or sparingly water soluble.

The present invention thus provides for an adhesive device useful for example, in the oral cavity, which includes an adhesive layer comprising a mixture of an acrylic acid polymer that is soluble or swellable in water to show adhesiveness and a water insoluble cellulose derivative, and a water insoluble or sparingly soluble backing layer.

The first characteristic of the present invention is that the device easily adheres to the ailing site in the oral cavity and that the adherence is sustained. Moreover, the adherence is not affected by any kind of oral movement such as drinking, eating, smoking or conversation. The second characteristic of the invention is that the adhesive device protects the ailing site because of its physical strength. The third characteristic is that the adhesive device gives less foreign body sensation because it becomes flexible upon swelling with saliva in the oral cavity, and also because it does not adhere to adjacent areas due to the water insoluble or sparingly soluble backing layer.

The fourth characteristic of the invention is that the release of the drug into tissue or saliva is sustained after application to oral mucosa when the drug is formulated in an adhesive layer.

The above characteristics of the present invention arise from the use of an adhesive layer which includes a water-soluble or swellable acrylic acid polymer, showing adhesiveness by dissolution or swelling in water, and a water insoluble cellulose derivative whereby the adhesive layer is attached to a water insoluble or sparingly soluble backing layer on one side thereof. It is impossible to achieve the purpose of the present invention without all three components, that is, the water-soluble or swellable acrylic acid polymer, water insoluble cellulose derivative and a water insoluble or sparingly soluble backing layer.

Any kind of water-soluble or swellable acrylic acid polymer can be used in the adhesive layer as long as the polymer or polymers show adhesiveness upon dissolution or swelling in water. For example, polyacrylic acid or partially cross-linked polyacrylic acid (acid type such as Carbopol) are preferable. The viscosity of the polyacrylic acid is preferably 100-200,000 mPa·s (cp) (10% w/w aq. soln. 25°C), most preferably 500-100,100 mPa·s (cp). Partially cross-linked polyacrylic acid is preferably Carbopol 934, 940, and 941 (BF Goodrich), Hiviswako 103, 104, 105 and 106 (Wako Junyaku).

As a water insoluble cellulose derivative, ethyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethylethyl cellulose, cellulose acetate, cellulose acetatephthalate, and hydroxypropyl methylcellulose phthalate can be used. However, one kind or combination of more than two kinds of the following polymers are preferable in terms of film forming capability and flexibility of the film; ethylcellulose, carboxymethylethyl cellulose, cellulose acetate, cellulose acetatephthalate and hydroxypropyl-methylcellulose phthalate. Although there is no limitation to the description of ethylcellulose, it is preferable that its ethoxy content is 45-49.5% and that its viscosity is 3-350 cp, especially 10-100 cp (5% w/w in toluene:ethanol=80:20, 25°C). For carboxymethylethyl cellulose, it is preferable that its carboxymethyl content is 4.8-27.2% and that the ethoxy content is 17.4-46.2%. The acetyl content of cellulose acetate is preferably 29.0-44.8%. For cellulose acetate-phthalate, it is preferable that its acetyl content is 17-22.0% or its phthalate content is 30.0-40.0%. Hydroxypropylmethylcellulose phthalate is preferably hydroxy-propylmethylcellulose phthalate 200731 or 200824 (Japanese Pharmacopeia).

The ratio (w/w) of acrylic acid polymer to water insoluble cellulose derivative is preferably 99:1-50:50, most preferably 98:2-70:30. This ratio gives good and sustained adhesiveness of an adhesive layer and does not give any foreign body sensation.

Any material can be used as a backing layer as long as it supports the adhesive layer, for example, polymer film, paper cloth, non-woven cloth or aluminum sheet. Considering the factor of edibility, however, a film consisting of one or two kinds of the following polymers is preferable: ethylcellulose, cellulose acetate, cellulose acetatephthalate, hydroxypropyl methylcellulose phthalate, vinylacetate resin or a pharmacologically acceptable water soluble polymer which is insolubilized by cross linking.

Although there is no limitation to the thickness of the adhesive layer and the backing layer, the thickness of the adhesive layer is preferably 10-1000 micrometers, especially 20-200 micrometers and the thickness of the backing layer is preferably 1-100 micrometers, especially 5-30 micrometers. The device

shape can be modified to any shape depending on the ailing site.

The adhesive device of the present invention can incorporate any compound into the components described above. For example, glycerin or polyethylene glycol can be incorporated as a plasticizer to make the adhesive layer flexible; polyalcohols such as propylene glycol can be used to control drug release; absorption promoters such as surfactants and Azone can be added; scents, flavoring agents, coloring agents, and preservatives can be also incorporated. Where one or more of these additional compounds are present, the total content of acrylic acid polymer and water insoluble cellulose derivative in the adhesive layer is preferably more than 50%.

Drugs (i.e., pharmaceutical preparations) can be incorporated into the adhesive device, and the duration of drug action is prolonged because of sustained release of the drug from the adhesive device. Although any drug can be used depending on the purpose of therapy, the following are exemplary:

1. anti-inflammatory, analgesic agents: content 0.1-5%
2. steroidal anti-inflammatory agents: content 0.002-0.5%
3. antihistamines: 0.1-2%
4. local anesthetics: 0.05-2%
5. bactericides and disinfectants: 0.01-10%
6. vasoconstrictor: 0.01-1%
7. hemostatics: 0.05-1%
8. chemotherapeutic drugs: 0.05 - 1%
9. antibiotics: 0.001-10%

Examples of anti-inflammatory, analgesic agents include acetaminophen, methyl salicylate, monoglycol salicylate, aspirin, mefenamic acid, flufenamic acid, indomethacin, diclofenac, alclofenac, diclofenac sodium, ibuprofen, ketoprofen, naproxen, pranoprofen, fenoprofen, sulindac, fenclofenac, clidanac, flurbiprofen, fentiazac, buprenorphine, piroxicam, phenylbutazone, oxyphenbutazone, clofezone, pentazocine, mepirizole, tiaramide hydrochloride, etc.

Examples of steroidal anti-inflammatory agents include hydrocortisone, predonisolone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, hydrocortisone acetate, predonisolone acetate, methylpredonisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, fluorometholone, beclomethasone dipropionate, etc.

Examples of antihistamines include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine hydrochloride, chlorpheniramine maleate, isothipendyl hydrochloride, tripeleminamine hydrochloride, promethazine hydrochloride, methdilazine hydrochloride, etc.

Examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, procaine hydrochloride, tetracaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine hydrochloride, mepivacaine, cocaine hydrochloride, piperocaine hydrochloride, etc.

Examples of bactericides and disinfectants include thimerosal, phenol, thymol, benzalkonium chloride, benzethonium chloride, chlorhexidine, povidone iodine, cetylpyridinium chloride, eugenol, trimethylammonium bromide, etc.

Examples of vasoconstrictors include naphazoline nitrate, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride, tramazoline hydrochloride, etc.

Examples of hemostatics include thrombin, phytonadione, protamine sulfate, aminocaproic acid, tranexamic acid, carbazochrome, carbaxochrome sodium sulfanate, rutin, hesperidin, etc.

Examples of chemotherapeutic drugs include sulfaminoxazole, sulfathiazole, sulfadiazine, homosulfamine, sulfisoxazole, sulfisomidine, sulfamethizole, nitrofurazone, etc.

Examples of antibiotics include penicillin, metacillin, oxacillin, cefalotin, cefaloridin, erythromycin, lincomycin, tetracycline, chlortetracycline, oxytetracycline, metacycline, chloramphenicol, kanamycin, streptomycin, gentamicin, bacitracin, cycloserine, etc.

The content of the pharmaceutical can be varied depending on the particular one employed. In general, however, the pharmaceutical content is 0.001-20%, and preferably 0.002-10% of the adhesive layer.

The method of preparation for the present device is not limited and various methods can be used, for example the adhesive layer components can be dissolved in solvent, spread on a flat surface and dried to form an adhesive layer. The backing layer components in solvent solution can then be spread over the adhesive layer and dried to form a backing layer.

The adhesive device can be used without incorporating a drug, for example, as a surgical pack or it can be used for therapeutic use with a drug in the adhesive layer. To apply to the oral mucosal membrane, the adhesive layer is placed on the ailing site. The adhesive layer becomes sticky by dissolution or swelling with saliva, whereupon it sticks to the ailing site.

When applied to an oral cavity, the present oral adhesive device easily sticks to the ailing site, its adhesiveness is sustained, it protects the ailing site, it gives less foreign body sensation, and its drug release is stable and sustained. The device thus provides protection of the ailing site and sustained drug action.

5 The following examples illustrate the invention. Percentages in the various formulations refer to weight percentage.

Example 1

10 Test of adhesiveness to lower jaw lip side gum, protectability and protrusion-like feeling in human volunteers.

Adhesive devices of the present invention (A,B,C,D, and E, the composition of each adhesive layer being shown in Table 1) and devices outside the scope of the invention were applied to the lower jaw lip
 15 side gums of healthy male volunteers. Activities of the volunteers were restricted according to the schedule below and the adhesiveness measured by the length of time before the device peeled off. Protectability was determined by the area of a patch five hours after application: no area change compared to the initial area (⊙) very good; more than 2/3 of the initial area remaining (○) good; more than 1/2 of the initial area remaining (△) adequate; less than 1/2 remaining (X) unsatisfactory. The degree of foreign body sensation
 20 was determined by the questionnaire after the test: very strong foreign body sensation (+ + +); strong foreign body sensation (+ +); foreign body sensation (+); slight foreign body sensation (±); no foreign body sensation (-). The results are summarized in Tables 2-4, which show the results both for each volunteer and the average.

25

30

35

40

45

50

55

Formulas of the Present Invention

1. Adhesive Layer

Table 1

	A	B	C	D	E
Acrylic acid polymer ¹					
polyacrylic acid	18	16	14	12	10
water insoluble cellulose derivative ²					
ethylcellulose	2	4	6	8	10
glycerin-fatty acid ester ³	2	2	2	2	2

1 Polyacrylic acid used had a viscosity of 100,000 cps for 10 % aq. soln.

2 Ethylcellulose used was Ethocel 45 cps (Dow Chemical, standard type, ethoxy content 48-40.5 %, viscosity of 5% soln. in toluene:ethanol=80:20 is 41-49 cps).

3 Glycerin-fatty acid ester used was Nikkol Mas-ASE (glycerin monostearate, Nikko Chemicals). The same glycerin-fatty acid ester was used for the other examples and the comparison samples.

Adhesive layer components were dissolved in ethanol, mixed, spread on a waxed paper, and dried at 40°C. The backing layer components were dissolved in ethanol and spread over the dried adhesive layer and dried at 40°C.

Comparison Sample F

1. Adhesive Layer

Polyacrylic Acid (100,000 cps at 10%)	18
Ethylcellulose (Ethocel 45 cp)	2
Glycerine-fatty acid Ester	2

The preparation method was the same as that for the device of the present invention except that no backing layer was used.

Comparison Sample G

1. Adhesive Layer

5

Ethylcellulose (Ethocel 45 cp)	20
Glycerine-fatty acid Ester	2

10

2. Backing Layer

15

Ethylcellulose (Ethocel 100 cp)	14
Castor Oil (plasticizer)	6

The preparation method was the same as that for the invented device.

20 Comparison Sample H

1. Adhesive Layer

25

Polyacrylic Acid (100,000 cps at 10 %)	20
Glycerin-fatty acid Ester	2

30 2. Backing Layer

35

Ethylcellulose (Ethocel 45 cp)	14
Castor Oil (plasticizer)	6

The preparation method was the same as that for the invented device.

40 Comparison Sample J

1. Adhesive Layer

45

Polyacrylic Acid (100,000 mPa*s (cps) at 10 %)	10
Hydroxypropyl Cellulose (Nihon Soda, HPC-L)	10
Glycerin-fatty acid Ester	2

50 2. Backing Layer

55

Ethylcellulose (Ethocel 100 mPa*s (cp))	14
Castor Oil (plasticizer)	6

The preparation method was the same as that for the invented device.

Comparison Sample K

1. Adhesive Layer

5

Hydroxypropyl Cellulose (Nihon Soda, HPC-L)	20
Polyacrylic Acid (Carbopol 934)	20

10 The components were mixed and compressed to obtain tablets of Comparison Example K.

Schedule

15	<u>Time</u>	<u>Activity</u>
	8:00	application of device
	10:00	tea
20	12:00	lunch
	13:00	determination of protectability
25	15:00	tea
	18:00	final observation

30 From the results in Tables 2-4, it can be seen that the device of the invention has a longer adhesion time and better protectability than the comparison devices. Moreover, devices A-E had less foreign body sensation.

Example 2

35

In Vitro Drug Release

Dibucain Hydrochloride was incorporated (1.0 % w/w) into device A in Example 1 and the in vitro release was measured.

40 A millipore filter was placed in a beaker filled with 100 ml of water. A device of the invention having a 20 mm diameter was placed on a millipore filter and the dibucaine concentration in water was measured at regular time intervals.

The result is shown in the Figure, in which the ordinates are the release rate in % and the abscissae time in hours. It is obvious from the Figure that the release rate is constant between 1 and 8 hours and it is
45 considered that drug action after application of the present device to the oral cavity can be sustained.

Although example formulas are shown below, the present invention is not to be limited thereby. Percentages in the examples are by weight.

50

55

Example Formula 1

1. Adhesive Layer

5

10

Polyacrylic Acid (100,000 cps at 10%)	20.0 %
Ethylcellulose (Ethocel 45 cp)	3.0
Glycerin-Fatty acid Ester	1.0
Methylparaoxybenzoic Acid	0.01
Ethanol	75.99

2. Backing Layer

15

20

Ethylcellulose (Ethocel 45 cp)	10.0 %
Castor Oil (plasticizer)	5.0
Ethanol	85.0

Adhesive layer components were dissolved, mixed, spread on waved paper and dried at 30 °C. Then the backing layer components were dissolved, spread over the adhesive layer and dried at room temperature. This device is used as an oral bandage to protect and promote the healing of an ailing site in the oral cavity.

25

Example Formula 2

1. Adhesive Layer

30

35

Polyacrylic Acid (30,000-50,000 at 8% aq. soln)	25.0 %
Cellulose Acetate (Daicel, Degree of Oxidation 55%)	3.5
Acetone	71.5%

2. Backing Layer

40

45

Cellulose Acetate (Degree of Oxidation 55%)	10.0%
Castor Oil	5.0
Acetone	85.0

Adhesive layer components were dissolved, mixed, spread over a waxed paper and dried at 40 °C to obtain an adhesive layer. Backing layer components were dissolved and sprayed on one side of the adhesive layer to thereby obtain the present device. This device can be used as an oral bandage.

50

55

Example Formula 3

1. Adhesive Layer

5

10

Polyacrylic Acid (Carbopol 941, Goodrich)	10.0%
Ethylcellulose (Ethocel 100cp)	2.0
Glycerin-Fatty acid Ester	1.0
Propylparaoxybenzoic Acid	0.02
Propylene Glycol	5.0
Dibucaine Hydrochloride	0.2
Ethanol	81.78

15

2. Backing Layer

20

Ethylcellulose (Ethocel 100 cp)	10.0
Castor Oil	5.0
Ethanol	85.0

Adhesive layer components were dissolved, mixed, spread on a waxed paper and dried at 40 °C to
 25 obtain an adhesive layer. Backing layer components were dissolved, spread over the adhesive layer and
 dried at 40 °C. The device is used as a preanesthetic for dental therapy.

Example Formula 4

30 1. Adhesive Layer

35

Polyacrylic Acid (Wako Junyaku, Hiviswako 104)	10.0%
Hydroxypropyl methylcellulose phthalate (Shinetsu Chemical, HPMCP200731)	2.0
Hydroxypropyl cellulose (Nisso HPC-L)	5.0
Polyethylene Glycol 400	5.0
Tranexamic Acid	1.0
Ethanol:Water (80:20) Mixture	77.0

40

2. Backing Layer

45

Ethylcellulose (Ethocel 10 cp)	20.0
Castor Oil	10.0
Ethanol	70.0

50 Adhesive layer components were dissolved, mixed, spread on waxed paper and dried at 40 °C to obtain
 an adhesive layer. Backing layer components were dissolved, spread over the adhesive layer and dried at
 40 °C. This device can be used as a hemostatic for periodontitis and also after pulling out a tooth.

While the above description is primarily directed to use of the adhesive device of the invention in the
 oral cavity, it will be appreciated that the invention can be used in other applications such as intravaginal,
 55 etc.

TABLE 2
Length of Adhesive Time (hours)

Volunteer No	1	2	3	4	5	Ave
Sample A	>10	>10	8	>10	>10	9.6
" B	9.5	>10	>10	>10	9	9.7
" C	8	9.5	7	8.5	>10	8.6
" D	6.5	7	8	6	>10	7.5
" E	5.5	6	8	7.5	6.5	6.7
Comparison Sample F	4	8.5	4	6	4	5.3
" G	0	0	0	0	0	0
" H	2	4	5.5	4	6	4.3
" I	4	6	4	5	7	5.2
" J	6	8	8	6	6	6.8
" K	4	6	8	6	4	5.6

TABLE 3
Protectability

Volunteer No	1	2	3	4	5	Ave
Sample A	⊙	⊙	⊙	⊙	⊙	⊙
" B	⊙	○	⊙	⊙	⊙	⊙
" C	⊙	⊙	○	△	⊙	○
" D	○	○	⊙	⊙	○	○
" E	△	⊙	○	△	○	○
Comparison Sample F	X	⊙	X	○	X	△
" G	X	X	X	X	X	X
" H	X	X	△	X	○	△
" I	X	○	X	△	△	△
" J	X	○	○	△	X	△
" K	X	△	○	○	X	△

Table 4
Degree of foreign body sensation

Volunteer No	1	2	3	4	5	Ave
Sample A	—	—	±	±	—	—
" B	—	±	—	±	—	—
" C	—	—	—	±	—	—
" D	—	±	±	±	±	±
" E	—	—	±	±	±	±
Comparison Sample F	++	++	+++	++	+	++
" G	—	—	—	—	—	—
" H	±	±	±	—	±	±
" I	+	—	—	±	+	±
" J	+	+	++	+	—	+
" K	+	++	+	++	++	++

Claims

1. An adhesive device for application to body tissue, comprising:
an adhesive layer having an adhesive surface adherable to body tissue; and
a water insoluble or sparingly water soluble backing layer secured over a surface of said adhesive layer opposite said adhesive surface;
wherein said adhesive layer comprises a mixture of at least one acrylic acid polymer that is soluble or swellable in water to show adhesiveness and a water insoluble cellulose derivative.
2. An adhesive device as claimed in claim 1, wherein the viscosity of said acrylic acid polymer is from about 100 to about 200,000 mPa·s (cp) in a 10% w/w aqueous solution at 25° C.
3. An adhesive device as claimed in claim 1 or claim 2, wherein said water insoluble cellulose derivate comprises ethylcellulose, carboxymethyl cellulose, cellulose acetate, cellulose acetate-phthalate or hydroxypropyl-methylcellulose phthalate.
4. An adhesive device as claimed in any preceding claim, wherein the weight ratio of said acrylic acid polymer to said water insoluble cellulose derivative is from about 99:1 to about 50:50.
5. An adhesive device as claimed in any preceding claim, wherein said backing layer is a polymer film, paper, cloth, non-woven cloth or aluminum sheet.
6. An adhesive device as claimed in any one of claims 1-4, wherein said backing is a polymer comprising ethylcellulose, cellulose acetate, cellulose acetatephthalate, hydroxypropyl methyl- cellulose phthalate, vinylacetate resin or a pharmacologically acceptable water soluble polymer which is insolubilized by cross linking.
7. An adhesive device as claimed in any preceding claim, wherein the thickness of said adhesive layer is from about 10 to about 1000 μm and wherein the thickness of said backing layer is from about 1 to about 100 μm .

8. An adhesive device as claimed in claim 7, wherein the thickness of said adhesive layer is from about 20 to about 200 μm and the thickness of said backing layer is from about 5 to about 30 μm .
9. An adhesive device as claimed in any preceding claim, wherein said adhesive layer further includes a pharmaceutical preparation.
10. An adhesive device as claimed in claim 9, wherein said pharmaceutical preparation comprises an analgesic anti-inflammatory agent, a steroidal anti-inflammatory agent, an antihistamine, a local anesthetic, a bactericide, a disinfectant, a vasoconstrictor, a hemostatic, a chemotherapeutic drug or an antibiotic, said pharmaceutical preparation being present in said adhesive layer in an amount of from about 0.001 to about 20 percent by weight.
11. An adhesive device as claimed in claim 10, wherein said pharmaceutical preparation comprises methylparaoxybenzoic acid.
12. An adhesive device as claimed in claim 10, wherein said pharmaceutical preparation comprises dibucaine hydrochloride.
13. An adhesive device as claimed in claim 10, wherein said pharmaceutical preparation comprises tranexamic acid.
14. A surgical packing comprising the adhesive device as claimed in claim 1.
15. An adhesive device including a pharmaceutical preparation, according to any one of claims 10 to 13, for use in application to body tissue, whereby in contact with a body fluid said pharmaceutical preparation is progressively released into said body tissue and/or body fluid.
16. An adhesive device according to claim 15 for use in application to body tissue in an oral cavity, whereby in contact with saliva said pharmaceutical preparation is progressively released into said body tissue and/or saliva.
17. An adhesive device according to claim 16 for use in application to gingival tissue, lip tissue or a tooth, whereby in contact with saliva said pharmaceutical preparation is progressively released into said gingival tissue, lip tissue or tooth and/or saliva.

Patentansprüche

1. Klebeeinrichtung zur Anwendung an Körpergewebe, bestehend aus: einer Klebeschicht mit einer am Körpergewebe haftenden Oberfläche und einer wasserunlöslichen oder in Wasser wenig löslichen Rückschicht, die auf eine Oberfläche der Klebeschicht abseitig von der klebenden Oberfläche aufgetragen ist, wobei die Klebeschicht besteht aus einer Mischung aus mindestens einem Acrylsäurepolymer, das unter Klebewirkung in Wasser löslich oder quellbar ist, und einem wasserunlöslichen Cellulosederivat.
2. Klebeeinrichtung gemäß Anspruch 1, wobei die Viskosität des Acrylsäurepolymeren zwischen etwa 100 bis 200000 mPa.s(cp) in einer 10%igen w/w-Lösung in Wasser bei 25 °C liegt.
3. Klebeeinrichtung gemäß Anspruch 1 oder 2, wobei das wasserunlösliche Cellulosederivat umfaßt Ethylcellulose, Carboxymethylcellulose, Celluloseacetat, Celluloseacetophthalat oder Hydroxypropylmethylcellulosephthalat.
4. Klebeeinrichtung gemäß einem jeden der vorangehenden Ansprüche, wobei das Gewichtsverhältnis des Acrylsäure-Polymeren zu dem wasserunlöslichen Cellulosederivat zwischen etwa 99 : 1 und etwa 50 : 50 liegt.
5. Klebeeinrichtung gemäß einem jeden der vorangehenden Ansprüche, wobei das Gewebe, Vliesgewebe oder einer Aluminiumschicht besteht.

6. Kleebeeinrichtung gemäß einem jeden der vorangehenden Ansprüche 1 bis 4, wobei die Rückschicht ein Polymer ist bestehend aus Ethylcellulose, Celluloseacetat, Celluloseacetophthalat, Hydroxypropylmethyl-cellulosephthalat, Venylacetatharz oder einem pharmakologisch annehmbaren wasserunlöslichen Polymeren, das durch Vernetzung unlöslich gemacht ist.
7. Kleebeeinrichtung gemäß einem jeden der vorangehenden Ansprüche, wobei die Dicke der Klebeschicht zwischen etwa 10 bis etwa 1000 µm und die Dicke der Rückschicht zwischen etwa 1 bis 100 µm liegen.
8. Kleebeeinrichtung gemäß Anspruch 7, wobei die Dicke der Klebeschicht zwischen etwa 20 und 200 µm und die Dicke der Rückschicht zwischen etwa 5 bis 30 µm liegen.
9. Kleebeeinrichtung gemäß einem jeden der vorangehenden Ansprüche, wobei die Klebeschicht weiterhin ein pharmazeutisches Mittel enthält.
10. Kleebeeinrichtung gemäß Anspruch 9, wobei das pharmazeutische Mittel ein analgetisch entzündungshemmendes Mittel, ein steroidales entzündungshemmendes Mittel, ein Lokalanästhetikum, ein Bakterizid, ein Desinfektionsmittel, ein gefäßverengendes Mittel, ein Hämostatikum, ein Chemotherapeutikum oder Antibiotikum ist und das pharmazeutische Mittel in der Klebeschicht in einer Menge zwischen etwa 0,001 bis etwa 20 Gew.-% vorliegt.
11. Kleebeeinrichtung gemäß Anspruch 10, wobei das pharmazeutische Mittel Methyl-p-oxybenzoesäure ist.
12. Kleebeeinrichtung gemäß Anspruch 10, wobei das pharmazeutische Mittel Dibucainhydrochlorid ist.
13. Kleebeeinrichtung gemäß Anspruch 10, wobei das pharmazeutische Mittel Tranexisäure ist.
14. Chirurgische Packung, enthaltend eine Kleebeeinrichtung gemäß Anspruch 1.
15. Kleebeeinrichtung mit einem pharmazeutischen Mittel gemäß Anspruch 10 bis 13, vorgesehen zur Anwendung an Körpergewebe, wobei durch die Berührung mit Körperflüssigkeit das pharmazeutische Mittel progressiv an das Körpergewebe und/oder die Körperflüssigkeit abgegeben wird.
16. Kleebeeinrichtung gemäß Anspruch 15, vorgesehen zur Anwendung in einer oralen Kavität, wobei durch die Berührung mit Speichel das pharmazeutische Mittel progressiv an das Körpergewebe und/oder den Speichel abgegeben wird.
17. Kleebeeinrichtung gemäß Anspruch 16, vorgesehen für die Anwendung an gingivales Gewebe, Lippen-Gewebe oder Zähne, wobei durch die Berührung mit Speichel das pharmazeutische Mittel progressiv an das gingivale Gewebe, das Lippen-Gewebe oder die Zähne und/oder den Speichel abgegeben wird.

Revendications

1. Dispositif adhésif pour application sur le tissu corporel, comprenant :
une couche adhésive ayant une surface adhésive collable au tissu corporel; et
une couche de renforcement insoluble dans l'eau ou difficilement soluble dans l'eau, fixée sur une surface de ladite couche adhésive opposée à ladite surface adhésive ;
ladite couche adhésive comprenant un mélange d'au moins un polymère d'acide acrylique qui est soluble ou gonfle dans l'eau pour faire preuve d'adhérence, et un dérivé cellulosique insoluble dans l'eau.
2. Dispositif adhésif selon la revendication 1, dans lequel la viscosité dudit polymère d'acide acrylique est comprise entre environ 100 et environ 200 000 mPa.s (cp) en solution aqueuse à 10 % p/p à 25 °C.
3. Dispositif adhésif selon la revendication 1 ou la revendication 2, dans lequel ledit dérivé cellulosique insoluble dans l'eau comprend l'éthylcellulose, la carboxyméthylcellulose, l'acétate de cellulose, l'acétate-phthalate de cellulose ou le phthalate d'hydroxyméthylcellulose.

4. Dispositif adhésif selon l'une quelconque des revendications précédentes, dans lequel le rapport pondéral dudit polymère d'acide acrylique audit dérivé cellulosique insoluble dans l'eau est compris entre environ 99:1 et environ 50:50.
5. Dispositif adhésif selon l'une quelconque des revendications précédentes, dans lequel ladite couche de renforcement est un film polymère, du papier, un tissu, un non-tissé ou une feuille d'aluminium.
6. Dispositif adhésif selon l'une quelconque des revendications 1 à 4, dans lequel ladite couche de renforcement est un polymère comprenant l'éthylcellulose, l'acétate de cellulose, l'acétate-phthalate de cellulose, le phtalate d'hydroxypropylméthylcellulose, une résine d'acétate de vinyle ou un polymère hydrosoluble pharmacologiquement acceptable, rendu insoluble par réticulation.
7. Dispositif adhésif selon l'une quelconque des revendications précédentes, dans lequel l'épaisseur de ladite couche adhésive est comprise entre environ 10 et environ 1 000 μm et dans lequel l'épaisseur de ladite couche de renforcement est comprise entre environ 1 et environ 100 μm .
8. Dispositif adhésif selon la revendication 7, dans lequel l'épaisseur de ladite couche adhésive est comprise entre environ 20 et environ 200 μm et l'épaisseur de ladite couche de renforcement est comprise entre environ 5 et environ 30 μm .
9. Dispositif adhésif selon l'une quelconque des revendications précédentes, dans lequel ladite couche adhésive comprend en outre une préparation pharmaceutique.
10. Dispositif adhésif selon la revendication 9, dans lequel ladite préparation pharmaceutique comprend un anti-inflammatoire antalgique, un anti-inflammatoire stéroïdien, un antihistamique, un anesthésique local, un bactéricide, un désinfectant, un vasoconstricteur, un hémostatique, un agent chimiothérapeutique ou un antibiotique, ladite préparation pharmaceutique étant présente dans ladite couche adhésive en une quantité comprise entre environ 0,001 et environ 20 % en poids.
11. Dispositif adhésif selon la revendication 10, dans lequel ladite préparation pharmaceutique comprend de l'acide méthylparaoxybenzoïque.
12. Dispositif adhésif selon la revendication 10, dans lequel ladite préparation pharmaceutique comprend du chlorhydrate de dibucaine.
13. Dispositif adhésif selon la revendication 10, dans lequel ladite préparation pharmaceutique comprend de l'acide tranexamique.
14. Tampon chirurgical comprenant le dispositif adhésif selon la revendication 1.
15. Dispositif adhésif comprenant une préparation pharmaceutique selon l'une quelconque des revendications 10 à 13, destiné à être appliqué sur le tissu corporel, ladite préparation pharmaceutique au contact avec un liquide organique étant libérée progressivement dans ledit tissu corporel et/ou liquide organique.
16. Dispositif adhésif selon la revendication 15, destiné à être appliqué sur le tissu corporel dans une cavité orale, ladite préparation pharmaceutique au contact avec la salive étant libérée progressivement dans ledit tissu corporel et/ou la salive.
17. Dispositif adhésif selon la revendication 16, destiné à l'application sur le tissu gingival, le tissu labial ou une dent, ladite substance pharmaceutique au contact avec la salive étant progressivement libérée dans lesdits tissu gingival, tissu labial ou dent et/ou salive.




FIGURE 1.